Lupin Limited , a leading pharmaceutical company, has issued a postal ballot notice seeking shareholder approval for two significant resolutions that could shape the company's leadership and executive compensation structure.

Independent Director Re-appointment

The first resolution proposes the re-appointment of Mr. Mark D. McDade as an Independent Director for a second five-year term, from January 28, 2026, to January 27, 2031. This appointment requires a special resolution as Mr. McDade will exceed 75 years of age during his tenure.

Mr. McDade, who has been serving on Lupin's board since January 2021, brings over 37 years of biopharmaceutical experience to the table. His expertise spans corporate governance, leadership, healthcare technology, and risk management, among other crucial areas.

Managing Director Remuneration Revision

The second resolution seeks approval for a substantial revision in the remuneration of Managing Director Nilesh D. Gupta, effective October 1, 2025. The proposed changes include:

• An increase in basic salary to ₹72.00 million per annum
• Total fixed cost rising to approximately ₹109.70 million
• Performance incentives of up to 100% of fixed cost

This revision comes after a peer benchmarking analysis revealed that Mr. Gupta's current compensation falls in the bottom 20% of comparable pharmaceutical companies.

Company Performance Under Current Leadership

Under Mr. Gupta's stewardship, Lupin has seen significant growth:

Voting Details

Shareholders can cast their votes through remote e-voting from August 27 to September 25, 2025. The results are expected to be announced by September 29, 2025.

These resolutions reflect Lupin's efforts to retain experienced leadership and align executive compensation with industry standards, potentially positioning the company for continued growth in the competitive pharmaceutical sector.

Lupin , a prominent player in the pharmaceutical industry, recently completed a significant block trade on the National Stock Exchange (NSE), demonstrating robust market activity in its shares.

Block Trade Details

The block trade, executed on the NSE, involved approximately 203,861 shares of Lupin. The transaction was valued at Rs. 39.99 crores, with each share priced at Rs. 1,961.70. This substantial trade highlights the continued interest in Lupin's stock among institutional investors and large market participants.

Market Implications

Block trades of this magnitude often indicate strategic moves by large investors or institutions. While the specific parties involved in this transaction have not been disclosed, such trades can sometimes signal shifting investor sentiments or portfolio realignments.

Company Overview

Lupin, headquartered in Mumbai, is a multinational pharmaceutical company known for its wide range of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). The company has a strong presence in various therapeutic segments and markets globally.

Recent Corporate Developments

In a separate corporate update, Lupin's Board of Directors has approved the re-appointment of Mr. Mark D. McDade as an Independent Director for a second term. This decision, subject to shareholder approval, extends Mr. McDade's tenure from January 28, 2026, to January 27, 2031.

Mr. McDade brings over four decades of experience in the biopharmaceutical industry to Lupin's board. His expertise spans areas such as:

• Corporate Governance
• Leadership & General Management
• Healthcare Pharma/Science & Technology
• Manufacturing, Quality & Supply Chain
• Risk Management
• ESG
• Information Technology
• Mergers & Acquisitions

This reappointment reflects Lupin's commitment to maintaining strong corporate governance and leveraging experienced leadership to guide its future strategies and operations.

The recent block trade, coupled with the board's decision to retain key leadership, underscores Lupin's active market presence and its focus on long-term strategic planning in the competitive pharmaceutical landscape.